– USA, TX – Aeglea Biotherapeutics, Inc., a biopharmaceutical company committed to developing enzyme based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the appointment of Sandy Mahatme and Russell Cox to its Board of Directors. Mr. Mahatme currently serves as Senior Vice President, Chief Financial Officer for Sarepta Therapeutics, and Mr. Cox serves as Executive Vice President and Chief Operating Officer for Jazz Pharmaceuticals.
“Sandy and Russell are leaders in the biotechnology industry whose experience and expertise will be invaluable to Aeglea. Sandy has a strong track record of success in business development and corporate strategic development, and Russell has extensive experience in both orphan disease and oncology sales and marketing and in building commercial infrastructures,” said David G. Lowe, Ph.D., co-founder, President and Chief Executive Officer of Aeglea. “They are joining our Board at an exciting time as we begin to advance our lead molecule, AEB1102, into clinical development as enzyme replacement therapy for patients with the inborn error of metabolism Arginase I deficiency, and for the treatment of cancer.”
Prior to joining Sarepta Therapeutics, Mr. Mahatme served in various roles of increasing responsibility at Celgene Corporation, including most recently as Senior Vice President of Corporate Development. While at Celgene, he built the treasury and tax functions before establishing the Corporate Development department, focused on strategic, targeted initiatives including commercial development in emerging markets, acquisitions and licensing and global manufacturing expansion. Prior to Celgene, he worked at Pfizer Inc., where he held senior roles in Business Development and Corporate Tax. He is also a member of the Board of Directors and Chairman of the Audit Committee of Flexion Therapeutics, Inc.
Prior to his position at Jazz Pharmaceuticals, a biopharmaceutical company specializing in the therapeutic categories of narcolepsy and oncology, Mr. Cox served as Senior Vice President and Chief Commercial Officer for Ipsen, U.S.A., a French pharmaceutical company developing and marketing treatments in oncology, endocrinology and neuromuscular disorders. Prior to that, he was Vice President of marketing at Tercica, which was acquired by Ipsen. Earlier in his career, he was Vice President of Marketing at Scios (acquired by Johnson & Johnson). Prior to that, he was a product team leader at Genentech, where he was responsible for the growth hormone franchise and led numerous product launches as a group product manager.
About Aeglea Biotherapeutics
Aeglea’s pipeline of engineered human enzymes includes the arginine degrading enzyme AEB1102, which we expect will enter into clinical trials in the second half of 2015. Three additional product candidates are in non-clinical research: AEB4104, which degrades homocystine, is being evaluated as a potential treatment for the inborn error of metabolism classical homocystinuria; AEB3103, which degrades cysteine/cysteine for treatment of hematologic and solid malignancies; and AEB2109, which degrades methionine, is being evaluated for the treatment of solid tumors.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.